阿司匹林
环氧合酶
止痛药
医学
药品
药理学
消炎药
塞来昔布
炎症
前列腺素内过氧化物合酶
化学
戊地昔布
依托三酯
罗非昔布
内科学
酶
生物化学
作者
Ravindran Nandakishore,Prasanna Raju Yalavarthi,Yengala R. Kiran,Malepati Rajapranathi
出处
期刊:Current Drug Discovery Technologies
[Bentham Science]
日期:2014-05-31
被引量:33
标识
DOI:10.2174/1570163811666140127123717
摘要
For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin. As the method of prostaglandin inhibition through COX is a common mechanism to both the wanted and unwanted effects of aspirin and non-aspirin NSAIDs, the COX enzyme becomes a target for drug designers for the development of the "safe aspirin". In the late 1990s, a new class of drug molecules collectively known as selective inhibitors of cyclooxygenase-2(Coxibs) was developed for the treatment of pain and inflammation. Coxibs developed were as efficacious as the common NSAIDs, but they are devoid of major side effect, the gastrointestinal bleeding. This review presents an overview on all the discovered COX-2 inhibitors, their physiological role, side effects and reasons of their withdrawal.
科研通智能强力驱动
Strongly Powered by AbleSci AI